Latest Breaking News On - Jay backstrom - Page 1 : comparemela.com

Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting

CAMBRIDGE, Mass. (BUSINESS WIRE) Jun 3, 2024

Dana farber cancer instituteUnited statesUnited kingdomRushmie nofsingerMolly macleodJay backstromToni choueiriGenitourinary gu oncology at dana farber cancer instituteLank centerScholar rock incExchange commissionAmerican society of clinical oncologyAmerican societyClinical oncologyAnnual meetingChief executive officer

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on.

United statesToni choueiriUlkan vaishampayanJay backstromJing marantzGenitourinary gu oncology at dana farber cancer instituteUniversity of michiganScholar rock incDivision of hematology oncologyAmerican society of clinical oncologyLank centerExchange commissionScholar rockAmerican societyClinical oncologyAnnual meeting

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

22.05.2024 - Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental . Seite 1

New yorkUnited statesJay backstromMo qatananiAmerican diabetes associationRock announces initiationNew preclinical data supportingChief scientific officerScholar rockInvestor eventChief executive officerScientific sessions

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani

CAMBRIDGE, Mass. (BUSINESS WIRE) Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointm.

United statesUnited kingdomAdicet bioJay backstromMo qatananiAmir nashatMolly macleodSynageva biopharmaRushmie nofsingerDavid hallalBaylor college of medicineInstitute for diabetesUniversity of californiaUniversity of pennsylvania school medicineExchange commissionCalifornia life sciences

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph D to Chief Scientific Officer

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph D to Chief Scientific Officer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesMo qatananiAmir nashatSynageva biopharmaAdicet bioJay backstromDavid hallalRoche holdingAmerican university of beirutCalifornia life sciencesScholar rock incAmgen incUniversity of californiaInstitute for diabetesAlexion pharmaceuticalsBaylor college of medicine